Werth VP, Joly P, Mimouni D, et al. - Researchers undertook this randomized, controlled trial to compare rituximab and mycophenolate mofetil as treatment options for pemphigus vulgaris. They allocated patients suffering from moderate-to-severe pemphigus vulgaris, in a 1:1 ratio, to receive intravenous rituximab (1000 mg on days 1, 15, 168, and 182) or oral mycophenolate mofetil (2 g per day), in addition to an oral glucocorticoid given on the same tapering schedule in the two groups. Findings demonstrated the superiority of rituximab, in terms of producing sustained complete remission at 52 weeks, over mycophenolate mofetil in these patients. A greater reduction in glucocorticoid use was offered by rituximab vs mycophenolate mofetil, but serious adverse events occurred in more patients in the rituximab group.